These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34301246)

  • 1. Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia.
    Kanter K; Gallagher R; Eweje F; Lee A; Gordon D; Landy S; Gasior J; Soto-Calderon H; Cronholm PF; Cocchiaro B; Weimer J; Roth A; Lankenau S; Brenner J
    Harm Reduct J; 2021 Jul; 18(1):75. PubMed ID: 34301246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What impacts the acceptability of wearable devices that detect opioid overdose in people who use opioids? A qualitative study.
    Tas B; Walker H; Lawn W; Matcham F; Traykova EV; Evans RAS; Strang J
    Drug Alcohol Rev; 2024 Jan; 43(1):213-225. PubMed ID: 37596977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania.
    Pizzicato LN; Johnson CC; Viner KM
    Subst Abus; 2020; 41(3):301-306. PubMed ID: 31644397
    [No Abstract]   [Full Text] [Related]  

  • 4. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey.
    Cooper-Ohm S; Habecker P; Humeniuk R; Bevins RA
    Harm Reduct J; 2024 Feb; 21(1):37. PubMed ID: 38336722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids.
    Winhusen T; Wilder C; Lyons MS; Theobald J; Kropp F; Lewis D
    Drug Alcohol Depend; 2020 Nov; 216():108265. PubMed ID: 32919098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "I don't go to funerals anymore": how people who use opioids grieve drug-related death in the US overdose epidemic.
    Schlosser AV; Hoffer LD
    Harm Reduct J; 2022 Oct; 19(1):110. PubMed ID: 36183109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: An observational study.
    Moustaqim-Barrette A; Papamihali K; Williams S; Ferguson M; Moe J; Purssell R; Buxton JA
    PLoS One; 2021; 16(10):e0259126. PubMed ID: 34714854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing opioid overdose with peer-administered naloxone: findings from a rural state.
    Hanson BL; Porter RR; Zöld AL; Terhorst-Miller H
    Harm Reduct J; 2020 Jan; 17(1):4. PubMed ID: 31918740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.
    Dunn KE; Barrett FS; Bigelow GE
    Addict Behav; 2018 Nov; 86():56-60. PubMed ID: 29625751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In brief: Higher-dose naloxone nasal spray (Kloxxado) for opioid overdose.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):151-152. PubMed ID: 34550963
    [No Abstract]   [Full Text] [Related]  

  • 14. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
    Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
    Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews.
    Razaghizad A; Windle SB; Filion KB; Gore G; Kudrina I; Paraskevopoulos E; Kimmelman J; Martel MO; Eisenberg MJ
    Am J Public Health; 2021 Aug; 111(8):e1-e12. PubMed ID: 34214412
    [No Abstract]   [Full Text] [Related]  

  • 16. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.
    Guadamuz JS; Alexander GC; Chaudhri T; Trotzky-Sirr R; Qato DM
    JAMA Netw Open; 2019 Jun; 2(6):e195388. PubMed ID: 31173125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose.
    Goldberg SA; Dworkis DA; Liao VT; Eyre AJ; Albert J; Fawcett MM; Narovec CM; DiClemente J; Weiner SG
    Prehosp Emerg Care; 2018; 22(6):788-794. PubMed ID: 29723076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with willingness to wear an electronic overdose detection device.
    Ahamad K; Dong H; Johnson C; Hyashi K; DeBeck K; Milloy MJ; Wood E
    Addict Sci Clin Pract; 2019 Jul; 14(1):23. PubMed ID: 31269963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid overdose prevention education in Texas during the COVID-19 pandemic.
    Mathias CW; Cavazos DM; McGlothen-Bell K; Crawford AD; Flowers-Joseph B; Wang Z; Cleveland LM
    Harm Reduct J; 2023 Mar; 20(1):37. PubMed ID: 36964600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.